Navigation Links
KV Pharmaceutical Suspends Product Manufacturing, Shipping
Date:1/26/2009

"could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, revenues, expenditures, resumption of distribution of tablet-form products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the introduction and impact of competitive products and pricing, including as a result of so- called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 On Tuesday, September 16th, 2014, ... first evening show, “KC After Dark.” Hosted by top ... Dark” will air every Tuesday at 8:00 p.m. EST. WRNW1 ... the 50th caller, and because of the amazing turnout for ... in mark with 500 callers. , During this comical, ...
(Date:9/22/2014)... people both exercise more and drink more , Study ... activity , Findings differ from past research on physical ... Medicine study finds that on days when people exercise ... more alcohol, too. , This is the only study ... for self-reporting physical activity and alcohol use. , "Monday ...
(Date:9/22/2014)... 22, 2014 Transvaginal mesh lawsuits ... continue to move forward in the federal multidistrict ... District of West Virginia, Bernstein Liebhard LLP reports. ... Order was issued by the Court on September ... to the upcoming trial for consolidated lawsuits involving ...
(Date:9/22/2014)... Boston, MA Up to 40 percent of patients ... may fail to remove all the cancerous tissue in ... Hospital (BWH) have successfully tested a tool they developed ... from normal tissue, thereby decreasing the chances for repeat ... online the week of September 22, 2014 in the ...
(Date:9/22/2014)... An inventor and anesthesiologist applied what she learned ... "My lower arm always became numb when I slept ... this problem," she said. "It’s better to be able ... 'fall asleep.'" , The Sleeping Pillow enables a user ... It avoids pain and restlessness by reducing pressure on ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:We drink more alcohol on gym days 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2
... SAGE and the European Society of Cardiology (ESC) have ... Acute Cardiovascular Care. The first issue will be published ... over 70,000 cardiology professionals across Europe and the Mediterranean, ... publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- From buying a Christmas tree to stringing ... and safety issues parents and guardians should consider during the holidays, ... offers the following tips to help keep children and the whole ... sure, if you select an artificial tree, that it is flame-resistant. ...
... The busy holiday season may disrupt many people,s daily routines, ... to remember to look after your teeth, an expert advises. ... treats and drink alcoholic beverages more than usual," Dr. George ... an academy news release. "Additionally, with their busy schedules ...
... It,s not likely that a policy of presumed consent would ... according to a new study. Under such a ... organs after death unless they explicitly forbid it while they,re ... say it would help ease the organ shortage in the ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... News) -- ,Draft recommendations meant to increase the number ... released Friday by the U.S. Food and Drug Administration. ... factors, and types of illness may cause women to ... men, according to the FDA. But, women are ...
Cached Medicine News:Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Pediatricians Offer Tips to Avoid Holiday Hazards 2Health News:Pediatricians Offer Tips to Avoid Holiday Hazards 3Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Presumed Consent Wouldn't Boost U.S. Organ Donation: Study 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:FDA Seeks to Get More Women Into Trials of Medical Devices 2
(Date:9/22/2014)... 22, 2014 Persistence Market Research ... Market Study on Ophthalmic Devices: Asia ... devices market was valued at USD 29,171.5 million in 2014 ... 6.5% from 2014 to 2020, to reach an estimated ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... 22, 2014  For many people experiencing issues ... facing the prospect of large, painful incisions and ... activities are also impacted, such as working, driving ... the problem, some patients even delay necessary treatment, ... lead to permanent damage for some conditions. ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...
... open-label study presented ... at ... AMLN ) today announced data showing that the use of ... in more patients achieving diabetes treatment goals of,improved glucose control without ...
Cached Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: